Bernhard Klaus Keppler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7601094/publications.pdf

Version: 2024-02-01

		5558	12910
517	26,500	82	131
papers	citations	h-index	g-index

532	532	532	16829
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Micro-droplet-based calibration for quantitative elemental bioimaging by LA-ICPMS. Analytical and Bioanalytical Chemistry, 2022, 414, 485-495.	1.9	20
2	Current and emerging mass spectrometry methods for the preclinical development of metal-based drugs: a critical appraisal. Analytical and Bioanalytical Chemistry, 2022, 414, 95-102.	1.9	2
3	Elemental analysis: an important purity control but prone to manipulations. Inorganic Chemistry Frontiers, 2022, 9, 412-416.	3.0	13
4	The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics, 2022, 14, 238.	2.0	14
5	Systematic Study on the Cytotoxic Potency of Commonly Used Dimeric Metal Precursors in Human Cancer Cell Lines. ChemistryOpen, 2022, 11, e202200019.	0.9	6
6	Versatile analytical methodology for evaluation of drug-like properties of potentially multi-targeting anticancer metallodrugs. Analytical Sciences, 2022, 38, 627-632.	0.8	2
7	Solution speciation and human serum protein binding of indium(III) complexes of 8-hydroxyquinoline, deferiprone and maltol. Journal of Biological Inorganic Chemistry, 2022, 27, 315-328.	1.1	1
8	A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance. Communications Chemistry, 2022, 5, .	2.0	31
9	The coordination modes of (thio)semicarbazone copper(II) complexes strongly modulate the solution chemical properties and mechanism of anticancer activity. Journal of Inorganic Biochemistry, 2022, 231, 111786.	1.5	19
10	Comparative Effects of Deferiprone and Salinomycin on Lead-Induced Disturbance in the Homeostasis of Intrarenal Essential Elements in Mice. International Journal of Molecular Sciences, 2022, 23, 4368.	1.8	2
11	Current Developments of N-Heterocyclic Carbene Au(I)/Au(III) Complexes toward Cancer Treatment. Biomedicines, 2022, 10, 1417.	1.4	11
12	Ameliorative effects of deferiprone and tetraethylammonium salt of salinomycinic acid on lead-induced toxicity in mouse testes. Environmental Science and Pollution Research, 2021, 28, 6784-6795.	2.7	3
13	Albumin-targeting of an oxaliplatin-releasing platinum(<scp>iv</scp>) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo. Chemical Science, 2021, 12, 12587-12599.	3.7	24
14	Development of a cobalt(<scp>iii</scp>)-based ponatinib prodrug system. Inorganic Chemistry Frontiers, 2021, 8, 2468-2485.	3.0	6
15	Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect. Nanoscale Advances, 2021, 3, 249-262.	2.2	14
16	Doubly derivatized poly(lactide)â€“albumin nanoparticles as blood vessel-targeted transport device for magnetic resonance imaging (MRI). Journal of Nanoparticle Research, 2021, 23, 1.	0.8	1
17	Die Wechselwirkung mit ribosomalen Proteinen begleitet die Stressinduktion des Wirkstoffkandidaten BOLDâ€100/KP1339 im endoplasmatischen Retikulum. Angewandte Chemie, 2021, 133, 5121-5126.	1.6	2
18	Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLDâ€100/KP1339 in the Endoplasmic Reticulum. Angewandte Chemie - International Edition, 2021, 60, 5063-5068.	7.2	39

#	Article	IF	Citations
19	Innentitelbild: Die Wechselwirkung mit ribosomalen Proteinen begleitet die Stressinduktion des Wirkstoffkandidaten BOLDâ€100/KP1339 im endoplasmatischen Retikulum (Angew. Chem. 10/2021). Angewandte Chemie, 2021, 133, 5006-5006.	1.6	0
20	Mass spectrometry techniques for imaging and detection of metallodrugs. Current Opinion in Chemical Biology, 2021, 61, 123-134.	2.8	28
21	Current trends and challenges in analysis and characterization of engineered nanoparticles in seawater. Talanta, 2021, 226, 122201.	2.9	15
22	Morphoâ€metabotyping the oxidative stress response. Scientific Reports, 2021, 11, 15471.	1.6	13
23	Toward a deeper and simpler understanding of serum protein-mediated transformations of magnetic nanoparticles by ICP-MS. Talanta, 2021, 229, 122287.	2.9	9
24	Establishing electron diffraction in chemical crystallography. Nature Reviews Chemistry, 2021, 5, 660-668.	13.8	37
25	Complex formation of an estrone-salicylaldehyde semicarbazone hybrid with copper(II) and gallium(III): Solution equilibria and biological activity. Journal of Inorganic Biochemistry, 2021, 220, 111468.	1.5	9
26	Thermodynamic Genome-Scale Metabolic Modeling of Metallodrug Resistance in Colorectal Cancer. Cancers, 2021, 13, 4130.	1.7	5
27	Structureâ€“Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands. Journal of Medicinal Chemistry, 2021, 64, 12132-12151.	2.9	34
28	Estroneâ€“salicylaldehyde N-methylated thiosemicarbazone hybrids and their copper complexes: solution structure, stability and anticancer activity in tumour spheroids. Journal of Biological Inorganic Chemistry, 2021, 26, 775-791.	1.1	5
29	Hunting for bis-bibenzyls in Primula veris subsp. macrocalyx (Bunge) LÃ¼di: Organ-specific accumulation and cytotoxic activity. Phytochemistry Letters, 2021, 44, 90-97.	0.6	3
30	Effects of N-terminus modified Hx-amides on DNA binding affinity, sequence specificity, cellular uptake, and gene expression. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128158.	1.0	1
31	Modified amino-dextrans as carriers of Gd-chelates for retrograde transport and visualization of peripheral nerves by magnetic resonance imaging (MRI). Journal of Inorganic Biochemistry, 2021, 222, 111495.	1.5	1
32	Water-soluble trithiolato-bridged dinuclear ruthenium(II) and osmium(II) arene complexes with bisphosphonate functionalized ligands as anticancer organometallics. Journal of Inorganic Biochemistry, 2021, 225, 111618.	1.5	1
33	Multifunctional Pt(<scp>iv</scp>) prodrug candidates featuring the carboplatin core and deferoxamine. Dalton Transactions, 2021, 50, 8167-8178.	1.6	9
34	Organometallic Receptors and Conjugates With Biomolecules in Bioorganometallic Chemistry. , 2021, , .		0
35	Liposomal formulations of anticancer copper(<scp>ii</scp>) thiosemicarbazone complexes. Dalton Transactions, 2021, 50, 16053-16066.	1.6	5
36	KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri. Journal of Biological Inorganic Chemistry, 2021, 26, 897-907.	1.1	3

#	Article	IF	Citations
37	The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivoâ€"A Comparison of O,O â€, S,O â€, and N , Nâ€•Chelate Effects. Chemistry - A European Journal, 2020, 26, 2211-2221.	1.7	8
38	Naphthoquinones of natural origin: Aqueous chemistry and coordination to half-sandwich organometallic cations. Journal of Organometallic Chemistry, 2020, 907, 121070.	0.8	6
39	First insights into the novel class of organometallic compounds bearing a bidentate selenopyridone coordination motif: Synthesis, characterization, stability and biological investigations. Inorganica Chimica Acta, 2020, 513, 119919.	1.2	6
40	Aluminum in Coffee. ACS Omega, 2020, 5, 15335-15343.	1.6	3
41	Synthetically Versatile Nitrogen Acyclic Carbene Stabilized Gold Nanoparticles. Chemistry - A European Journal, 2020, 26, 15859-15862.	1.7	9
42	Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs. Inorganic Chemistry, 2020, 59, 17794-17810.	1.9	11
43	Complex formation and cytotoxicity of Triapine derivatives: a comparative solution study on the effect of the chalcogen atom and NH-methylation. Dalton Transactions, 2020, 49, 16887-16902.	1.6	22
44	Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. Journal of Medicinal Chemistry, 2020, 63, 13719-13732.	2.9	33
45	C,N-chelated diaminocarbene platinum(II) complexes derived from 3,4-diaryl-1H-pyrrol-2,5-diimines and cis-dichlorobis(isonitrile)platinum(II): Synthesis, cytotoxicity, and catalytic activity in hydrosilylation reactions. Journal of Organometallic Chemistry, 2020, 923, 121435.	0.8	11
46	Improving the Stability of Maleimideâ€"Thiol Conjugation for Drug Targeting. Chemistry - A European Journal, 2020, 26, 15867-15870.	1.7	29
47	MR Imaging of Peripheral Nerves Using Targeted Application of Contrast Agents: An Experimental Proof-of-Concept Study. Frontiers in Medicine, 2020, 7, 613138.	1.2	3
48	An ICP-MS-based assay for characterization of gold nanoparticles with potential biomedical use. Analytical Biochemistry, 2020, 611, 114003.	1.1	6
49	IntroducingN-,P-, andS-donor leaving groups: an investigation of the chemical and biological properties of ruthenium, rhodium and iridium thiopyridone piano stool complexes. Dalton Transactions, 2020, 49, 15693-15711.	1.6	10
50	High Copper Complex Stability and Slow Reduction Kinetics as Key Parameters for Improved Activity, Paraptosis Induction, and Impact on Drug-Resistant Cells of Anticancer Thiosemicarbazones. Antioxidants and Redox Signaling, 2020, 33, 395-414.	2.5	28
51	How versatile is the use of ultrafiltration to study biointeractions of therapeutic metallodrugs?. Analytical Biochemistry, 2020, 598, 113697.	1.1	5
52	Heavy Metal Extraction under Environmentally Relevant Conditions Using 3-Hydroxy-2-Naphthoate-Based Ionic Liquids: Extraction Capabilities vs. Acute Algal Toxicity. Applied Sciences (Switzerland), 2020, 10, 3157.	1.3	8
53	Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib. Molecules, 2020, 25, 1149.	1.7	6
54	Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIÎ± inhibitors. Journal of Biological Inorganic Chemistry, 2020, 25, 451-465.	1.1	16

#	Article	IF	Citations
55	Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib. Bioorganic Chemistry, 2020, 99, 103778.	2.0	11
56	Tetra-(p-tolyl)antimony(III)-Containing Heteropolytungstates, [{(p-tolyl)Sb^{III}}₄(A-Î±-XW₉O₃₄)₂]^{nâ^'} (X = P, As, or Ge): Synthesis, Structure, and Study of Antibacterial and Antitumor Activity. Inorganic Chemistry, 2020, 59, 2978-2987.	1.9	15
57	Novel phthiocol-based organometallics with tridentate coordination motif and their unexpected cytotoxic behaviour. Dalton Transactions, 2020, 49, 1393-1397.	1.6	8
58	Synthesis, Modification, and Biological Evaluation of a Library of Novel Waterâ€Soluble Thiopyridoneâ€Based Organometallic Complexes and Their Unexpected (Biological) Behavior. Chemistry - A European Journal, 2020, 26, 5419-5433.	1.7	10
59	Investigations on the Anticancer Potential of Benzothiazole-Based Metallacycles. Frontiers in Chemistry, 2020, 8, 209.	1.8	10
60	The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts. Molecular and Cellular Proteomics, 2020, 19, 478-489.	2.5	12
61	Plecstatin-1 induces an immunogenic cell death signature in colorectal tumour spheroids. Metallomics, 2020, 12, 2121-2133.	1.0	27
62	Fine-Tuning the Activation Mode of an 1,3-Indandione-Based Ruthenium(II)-Cymene Half-Sandwich Complex by Variation of Its Leaving Group. Molecules, 2019, 24, 2373.	1.7	7
63	Rutheniumâ€“arene complexes bearing naphthyl-substituted 1,3-dioxoindan-2-carboxamides ligands for G-quadruplex DNA recognition. Dalton Transactions, 2019, 48, 12040-12049.	1.6	20
64	Comparative Studies on the Human Serum Albumin Binding of the Investigational EGFR Inhibitor KP2187, Its Hypoxia-Activated Cobalt Complex, and a Series of Clinically Approved Inhibitors. Proceedings (mdpi), 2019, 22, .	0.2	0
65	Targeting G-quadruplexes with Organic Dyes: Chelerythrineâ€“DNA Binding Elucidated by Combining Molecular Modeling and Optical Spectroscopy. Antioxidants, 2019, 8, 472.	2.2	15
66	Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics. Metallomics, 2019, 11, 1716-1728.	1.0	21
67	Synthesis, Characterization, Cytotoxicity, and Time-Dependent NMR Spectroscopic Studies of (SP) Tj ETQq1 1 0.784314 rgBT /Overlo Journal of Inorganic Chemistry, 2019, 2019, 856-864.	1.0	3
68	Mercury, silver, selenium and other trace elements in three cyprinid fish species from the Vaal Dam, South Africa, including implications for fish consumers. Science of the Total Environment, 2019, 659, 1158-1167.	3.9	25
69	An improved protocol for ICP-MS-based assessment of the cellular uptake of metal-based nanoparticles. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 300-304.	1.4	14
70	Interplay of Three G-Quadruplex Units in the KIT Promoter. Journal of the American Chemical Society, 2019, 141, 10205-10213.	6.6	38
71	Subcellular Duplex DNA and Gâ€Quadruplex Interaction Profiling of a Hexagonal Pt II Metallacycle. Angewandte Chemie, 2019, 131, 8091-8096.	1.6	10
72	Subcellular Duplex DNA and Gâ€Quadruplex Interaction Profiling of a Hexagonal Pt^{II} Metallacycle. Angewandte Chemie - International Edition, 2019, 58, 8007-8012.	7.2	39

#	Article	IF	Citations
73	Zweifel an einem Dogma: Hydrolyse Ãquatorialer Liganden von Pt^{IV}â€Komplexen unter physiologischen Bedingungen. Angewandte Chemie, 2019, 131, 7542-7547.	1.6	5
74	A simple assay for probing transformations of superparamagnetic iron oxide nanoparticles in human serum. Chemical Communications, 2019, 55, 4270-4272.	2.2	13
75	A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt^{IV} Complexes under Physiological Conditions. Angewandte Chemie - International Edition, 2019, 58, 7464-7469.	7.2	46
76	Synthesis, characterization, lipophilicity and cytotoxic properties of novel bis(carboxylato)oxalatobis(1-propylamine)platinum(IV) complexes. Inorganica Chimica Acta, 2019, 491, 76-83.	1.2	3
77	First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. Metallomics, 2019, 11, 1044-1048.	1.0	92
78	Synthesis, characterization, cytotoxic activity, and 19F NMR spectroscopic investigations of (OC-6-33)-diacetato(ethane-1,2-diamine)bis(3,3,3-trifluoropropanoato)platinum(IV) and its platinum(II) counterpart. Inorganica Chimica Acta, 2019, 490, 190-199.	1.2	6
79	Single Spheroid Metabolomics: Optimizing Sample Preparation of Three-Dimensional Multicellular Tumor Spheroids. Metabolites, 2019, 9, 304.	1.3	16
80	Chemical imaging and assessment of cadmium distribution in the human body. Metallomics, 2019, 11, 2010-2019.	1.0	58
81	Synthesis, Characterization and inâ€...vitro Studies of a Cathepsin Bâ€Cleavable Prodrug of the VEGFR Inhibitor Sunitinib. Chemistry and Biodiversity, 2019, 16, e1800520.	1.0	9
82	Natural iron fertilization of the coastal ocean by â€œblackwater riversâ€• Science of the Total Environment, 2019, 656, 952-958.	3.9	15
83	Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes. Journal of Inorganic Biochemistry, 2019, 190, 85-97.	1.5	32
84	Analytical methodology for studying cellular uptake, processing and localization of gold nanoparticles. Analytica Chimica Acta, 2019, 1052, 1-9.	2.6	28
85	Metal Drugs and the Anticancer Immune Response. Chemical Reviews, 2019, 119, 1519-1624.	23.0	237
86	Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxidants and Redox Signaling, 2019, 30, 1062-1082.	2.5	137
87	Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 308-347.	0.8	14
88	Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS. Metallomics, 2018, 10, 388-396.	1.0	29
89	Comparison of metabolic pathways of different Î±-N-heterocyclic thiosemicarbazones. Analytical and Bioanalytical Chemistry, 2018, 410, 2343-2361.	1.9	12
90	N- and S-donor leaving groups in triazole-based ruthena(<scp>ii</scp>)cycles: potent anticancer activity, selective activation, and mode of action studies. Dalton Transactions, 2018, 47, 4625-4638.	1.6	18

#	Article	IF	Citations
91	Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1342-1347.	1.0	5
92	The impact of whole human blood on the kinetic inertness of platinum(<scp>iv</scp>) prodrugs â€“ an HPLC-ICP-MS study. Dalton Transactions, 2018, 47, 5252-5258.	1.6	20
93	Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. Inorganic Chemistry, 2018, 57, 2851-2864.	1.9	45
94	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. OncoImmunology, 2018, 7, e1424676.	2.1	35
95	Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187. Journal of Pharmaceutical and Biomedical Analysis, 2018, 154, 321-331.	1.4	20
96	A comparative study of Î±- N -pyridyl thiosemicarbazones: Spectroscopic properties, solution stability and copper(II) complexation. Inorganica Chimica Acta, 2018, 472, 264-275.	1.2	22
97	Structureâ€“activity relationships for ruthenium and osmium anticancer agents â€“ towards clinical development. Chemical Society Reviews, 2018, 47, 909-928.	18.7	330
98	The interaction of Schiff Base complexes of nickel(II) and zinc(II) with duplex and G-quadruplex DNA. Journal of Inorganic Biochemistry, 2018, 178, 106-114.	1.5	29
99	Complexes of pyridoxal thiosemicarbazones formed with vanadium(IV/V) and copper(II): Solution equilibrium and structure. Inorganica Chimica Acta, 2018, 472, 243-253.	1.2	17
100	Solvent Bar Micro-Extraction of Heavy Metals from Natural Water Samples Using 3-Hydroxy-2-Naphthoate-Based Ionic Liquids. Molecules, 2018, 23, 3011.	1.7	15
101	Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis. Scientific Reports, 2018, 8, 17198.	1.6	24
102	New Variations on the Theme of Gold(III) C^{â^§}N^{â^§}N Cyclometalated Complexes as Anticancer Agents: Synthesis and Biological Characterization. Inorganic Chemistry, 2018, 57, 14852-14865.	1.9	28
103	Development and Validation of Liquid Chromatography-Based Methods to Assess the Lipophilicity of Cytotoxic Platinum(IV) Complexes. Inorganics, 2018, 6, 130.	1.2	30
104	The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition. Cell Death and Disease, 2018, 9, 1052.	2.7	38
105	The Impact of Leaving Group Variation on the Anticancer Activity of Molybdenocenes. Organometallics, 2018, 37, 3909-3916.	1.1	8
106	Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SECâ€“ICPâ€“MS. Monatshefte FÃ¼r Chemie, 2018, 149, 1719-1726.	0.9	22
107	Critical assessment of different methods for quantitative measurement of metallodrug-protein associations. Analytical and Bioanalytical Chemistry, 2018, 410, 7211-7220.	1.9	17
108	Fluorescent organometallic rhodium(I) and ruthenium(II) metallodrugs with 4-ethylthio-1,8-naphthalimide ligands: Antiproliferative effects, cellular uptake and DNA-interaction. European Journal of Medicinal Chemistry, 2018, 156, 148-161.	2.6	46

#	Article	IF	Citations
109	Solvent bar micro-extraction for greener application of task specific ionic liquids in multi-elemental extraction. Journal of Cleaner Production, 2018, 201, 22-27.	4.6	14
110	Understanding the interactions of diruthenium anticancer agents with amino acids. Journal of Biological Inorganic Chemistry, 2018, 23, 1159-1164.	1.1	13
111	Studies of KP46 and KP1019 and the Hydrolysis Product of KP1019 in Lipiodol Emulsions: Preparation and Initial Characterizations as Potential Theragnostic Agents. Current Drug Delivery, 2018, 15, 134-142.	0.8	5
112	Novel 3-Hydroxy-2-Naphthoate-Based Task-Specific Ionic Liquids for an Efficient Extraction of Heavy Metals. Frontiers in Chemistry, 2018, 6, 172.	1.8	35
113	Synthesis and Biological Evaluation of Organometallic Complexes Bearing Bisâ€1,8â€naphthalimide Ligands. European Journal of Inorganic Chemistry, 2018, 2018, 3104-3112.	1.0	25
114	Uranium concentrations in sediment pore waters of Lake Neusiedl, Austria. Science of the Total Environment, 2018, 633, 981-988.	3.9	22
115	Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 2632-2643.	1.7	22
116	Structural and solution equilibrium studies on half-sandwich organorhodium complexes of (N,N) donor bidentate ligands. New Journal of Chemistry, 2018, 42, 11174-11184.	1.4	18
117	Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse. Scientific Reports, 2017, 7, 40966.	1.6	25
118	Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research. Metallomics, 2017, 9, 365-381.	1.0	54
119	{Ru(CO)_x}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. Dalton Transactions, 2017, 46, 3025-3040.	1.6	27
120	Comparative studies of oxaliplatin-based platinum(<scp>iv</scp>) complexes in different in vitro and in vivo tumor models. Metallomics, 2017, 9, 309-322.	1.0	60
121	Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition. Journal of Experimental and Clinical Cancer Research, 2017, 36, 52.	3.5	28
122	EGFR-targeting peptide-coupled platinum(IV) complexes. Journal of Biological Inorganic Chemistry, 2017, 22, 591-603.	1.1	23
123	Synthesis, Characterization, and Time-Dependent NMR Spectroscopy Studies of (SP-4-2)-[(trans-1R,2R/1S,2S-15N2)-Cyclohexane-1,2-diamine][(13C2)oxalato]platinum(II). European Journal of Inorganic Chemistry, 2017, 2017, 2347-2354.	1.0	6
124	Impact of the equatorial coordination sphere on the rate of reduction, lipophilicity and cytotoxic activity of platinum(IV) complexes. Journal of Inorganic Biochemistry, 2017, 174, 119-129.	1.5	25
125	Post-digestion stabilization of osmium enables quantification by ICP-MS in cell culture and tissue. Analyst, The, 2017, 142, 2327-2332.	1.7	17
126	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. Angewandte Chemie - International Edition, 2017, 56, 8267-8271.	7.2	97

#	Article	IF	Citations
127	Amidoxime platinum(<scp>ii</scp>) complexes: pH-dependent highly selective generation and cytotoxic activity. New Journal of Chemistry, 2017, 41, 6840-6848.	1.4	11
128	Functionalization of Ruthenium(II)(Î·⁶â€pâ€cymene)(3â€hydroxyâ€2â€pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. ChemPlusChem, 2017, 82, 841-847.	1.3	13
129	Heavy metals in the mallard Anas platyrhynchos from eastern Austria. Science of the Total Environment, 2017, 580, 670-676.	3.9	26
130	Metal NHC Complexes with Naphthalimide Ligands as DNAâ€Interacting Antiproliferative Agents. ChemMedChem, 2017, 12, 214-225.	1.6	28
131	Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates. Inorganic Chemistry, 2017, 56, 528-541.	1.9	52
132	An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo. Chemical Science, 2017, 8, 2241-2250.	3.7	114
133	Î²-O-4 type dilignol compounds and their iron complexes for modeling of iron binding to humic acids: synthesis, characterization, electrochemical studies and algal growth experiments. New Journal of Chemistry, 2017, 41, 11546-11555.	1.4	5
134	Platinum(IV) Complexes Featuring Axial Michael Acceptor Ligands - Synthesis, Characterization, and Cytotoxicity. European Journal of Inorganic Chemistry, 2017, 2017, 4049-4054.	1.0	12
135	Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates. Dalton Transactions, 2017, 46, 12114-12124.	1.6	32
136	Antiproliferative Copper(II) and Platinum(II) Complexes with Bidentate N,Nâ€Donor Ligands. European Journal of Inorganic Chemistry, 2017, 2017, 3115-3124.	1.0	13
137	Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. Cancer Letters, 2017, 404, 79-88.	3.2	44
138	InnenrÃ¼cktitelbild: Ein Organoruthenium‐Tumortherapeutikum mit unerwartet hoher SelektivitÃt fÃ¼r Plectin (Angew. Chem. 28/2017). Angewandte Chemie, 2017, 129, 8415-8415.	1.6	0
139	Ein Organoruthenium‐Tumortherapeutikum mit unerwartet hoher SelektivitÃt fÃ¼r Plectin. Angewandte Chemie, 2017, 129, 8379-8383.	1.6	14
140	Multifunctional Î±_vÎ²₆ Integrin-Specific Peptide–Pt(IV) Conjugates for Cancer Cell Targeting. Bioconjugate Chemistry, 2017, 28, 2429-2439.	1.8	18
141	Fast High-Resolution Laser Ablation-Inductively Coupled Plasma Mass Spectrometry Imaging of the Distribution of Platinum-Based Anticancer Compounds in Multicellular Tumor Spheroids. Analytical Chemistry, 2017, 89, 12641-12645.	3.2	44
142	Understanding the metabolism of the anticancer drug Triapine: electrochemical oxidation, microsomal incubation and in vivo analysis using LC-HRMS. Analyst, The, 2017, 142, 3165-3176.	1.7	18
143	Comparative equilibrium and structural studies of new pentamethylcyclopentadienyl rhodium complexes bearing (O,N) donor bidentate ligands. Journal of Organometallic Chemistry, 2017, 846, 287-295.	0.8	10
144	Oxaliplatin reacts with DMSO only in the presence of water. Dalton Transactions, 2017, 46, 8929-8932.	1.6	28

#	Article	IF	Citations
145	DNA or protein? Capillary zone electrophoresisâ€“mass spectrometry rapidly elucidates metallodrug binding selectivity. Chemical Communications, 2017, 53, 8002-8005.	2.2	26
146	Thioglycolate-based task-specific ionic liquids: Metal extraction abilities vs acute algal toxicity. Journal of Hazardous Materials, 2017, 340, 113-119.	6.5	29
147	Synthetic iron complexes as models for natural iron-humic compounds: Synthesis, characterization and algal growth experiments. Science of the Total Environment, 2017, 577, 94-104.	3.9	32
148	Task-specific thioglycolate ionic liquids for heavy metal extraction: Synthesis, extraction efficacies and recycling properties. Journal of Hazardous Materials, 2017, 324, 241-249.	6.5	82
149	Response Profiling Using Shotgun Proteomics Enables Global Metallodrug Mechanisms of Action To Be Established. Chemistry - A European Journal, 2017, 23, 1881-1890.	1.7	30
150	Lowâ€Generation Polyamidoamine Dendrimers as Drug Carriers for Platinum(IV) Complexes. European Journal of Inorganic Chemistry, 2017, 2017, 1713-1720.	1.0	20
151	Enhancing the Cytotoxic Activity of Anticancer Pt^{IV} Complexes by Introduction of Lonidamine as an Axial Ligand. European Journal of Inorganic Chemistry, 2017, 2017, 1785-1791.	1.0	29
152	Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin. Bioinorganic Chemistry and Applications, 2017, 2017, 1-6.	1.8	5
153	Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy. Oncotarget, 2016, 7, 1242-1261.	0.8	32
154	Photoreduction of Terrigenous Feâ€Humic Substances Leads to Bioavailable Iron in Oceans. Angewandte Chemie - International Edition, 2016, 55, 6417-6422.	7.2	24
155	DNAâ€Binding and Anticancer Activity of Pyreneâ€Imidazolium Derivatives. ChemistrySelect, 2016, 1, 6755-6761.	0.7	10
156	Molecular mode of action of NKP-1339 â€“ a clinically investigated ruthenium-based drug â€“ involves ER- and ROS-related effects in colon carcinoma cell lines. Investigational New Drugs, 2016, 34, 261-268.	1.2	96
157	X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism. Journal of Medicinal Chemistry, 2016, 59, 5894-5903.	2.9	113
158	Another step toward DNA selective targeting: Ni^{II} and Cu^{II} complexes of a Schiff base ligand able to bind gene promoter G-quadruplexes. Dalton Transactions, 2016, 45, 7758-7767.	1.6	49
159	Towards targeting anticancer drugs: ruthenium(<scp>ii</scp>)â€“arene complexes with biologically active naphthoquinone-derived ligand systems. Dalton Transactions, 2016, 45, 13091-13103.	1.6	45
160	Benzoic hydroxamate-based iron complexes as model compounds for humic substances: synthesis, characterization and algal growth experiments. RSC Advances, 2016, 6, 40238-40249.	1.7	21
161	Novel thiosalicylate-based ionic liquids for heavy metal extractions. Journal of Hazardous Materials, 2016, 314, 164-171.	6.5	82
162	G-quadruplex vs. duplex-DNA binding of nickel(II) and zinc(II) Schiff base complexes. Journal of Inorganic Biochemistry, 2016, 161, 115-121.	1.5	41

#	Article	IF	Citations
163	Targeting a Targeted Drug: An Approach Toward Hypoxiaâ€Activatable Tyrosine Kinase Inhibitor Prodrugs. ChemMedChem, 2016, 11, 2410-2421.	1.6	18
164	Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes. Macromolecular Bioscience, 2016, 16, 1239-1249.	2.1	27
165	Accurate high throughput quantification of selenium in biological samples â€“ the potential of combining isotope dilution ICP-tandem mass spectrometry with flow injection. Journal of Analytical Atomic Spectrometry, 2016, 31, 2227-2232.	1.6	13
166	Thiomaltolâ€Based Organometallic Complexes with 1â€Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior. Chemistry - A European Journal, 2016, 22, 17269-17281.	1.7	32
167	Flavonoidâ€Based Organometallics with Different Metal Centers â€“ Investigations of the Effects on Reactivity and Cytotoxicity. European Journal of Inorganic Chemistry, 2016, 2016, 240-246.	1.0	21
168	Nanoformulations of anticancer thiosemicarbazones to reduce methemoglobin formation and improve anticancer activity. RSC Advances, 2016, 6, 55848-55859.	1.7	11
169	Impact of Stepwise NH₂-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention. Journal of Medicinal Chemistry, 2016, 59, 6739-6752.	2.9	42
170	Anticancer metal drugs and immunogenic cell death. Journal of Inorganic Biochemistry, 2016, 165, 71-79.	1.5	107
171	Turbulent flow chromatography in combination with HPLC-ICP-MS for high-throughput analysis of free, intact metal based drugs in biomedical samples. Journal of Analytical Atomic Spectrometry, 2016, 31, 1811-1817.	1.6	5
172	Photoreduction of Terrigenous Feâ€Humic Substances Leads to Bioavailable Iron in Oceans. Angewandte Chemie, 2016, 128, 6527-6532.	1.6	10
173	The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. Journal of Inorganic Biochemistry, 2016, 160, 264-274.	1.5	40
174	Sphagnum-dominated bog systems are highly effective yet variable sources of bio-available iron to marine waters. Science of the Total Environment, 2016, 556, 53-62.	3.9	32
175	Behavior of platinum(<scp>iv</scp>) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. Metallomics, 2016, 8, 422-433.	1.0	39
176	Mass Spectrometry Uncovers Molecular Reactivities of Coordination and Organometallic Gold(III) Drug Candidates in Competitive Experiments That Correlate with Their Biological Effects. Inorganic Chemistry, 2016, 55, 4248-4259.	1.9	53
177	LA-ICP-MS imaging in multicellular tumor spheroids â€“ a novel tool in the preclinical development of metal-based anticancer drugs. Metallomics, 2016, 8, 398-402.	1.0	38
178	Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles. Journal of Biological Inorganic Chemistry, 2016, 21, 347-356.	1.1	25
179	Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action. Journal of Inorganic Biochemistry, 2016, 160, 250-255.	1.5	94
180	Synthesis, characterisation and cytotoxicity of (PHEN-4-MeDACH). Inorganica Chimica Acta, 2016, 441, 152-156.	1.2	4

#	Article	IF	Citations
181	Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics. Dalton Transactions, 2016, 45, 724-733.	1.6	20
182	Differences in protein binding and excretion of Triapine and its Fe(III) complex. Journal of Inorganic Biochemistry, 2016, 160, 61-69.	1.5	20
183	Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling. Oncotarget, 2016, 7, 84556-84574.	0.8	15
184	Metal Ions and Metal Complexes in Alzheimer's Disease. Current Pharmaceutical Design, 2016, 22, 3996-4010.	0.9	28
185	Extraction of natural radionuclides from aqueous solutions by novel maltolate-based task-specific ionic liquids. Journal of Radioanalytical and Nuclear Chemistry, 2015, 303, 2483-2488.	0.7	14
186	Expanding on the Structural Diversity of Flavone- Derived RutheniumII(Æž6-arene) Anticancer Agents. Metallodrugs, 2015, 1, .	1.7	15
187	Bisâ€•and Tetrakis(carboxylato)platinum(IV) Complexes with Mixed Axial Ligands â€“ Synthesis, Characterization, and Cytotoxicity. Chemistry and Biodiversity, 2015, 12, 559-574.	1.0	7
188	Rhodium(I) N-Heterocyclic Carbene Bioorganometallics as in Vitro Antiproliferative Agents with Distinct Effects on Cellular Signaling. Journal of Medicinal Chemistry, 2015, 58, 9591-9600.	2.9	44
189	Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application. Journal of Biological Inorganic Chemistry, 2015, 20, 89-99.	1.1	47
190	1,3-Dioxoindan-2-carboxamides as Bioactive Ligand Scaffolds for the Development of Novel Organometallic Anticancer Drugs. Organometallics, 2015, 34, 848-857.	1.1	25
191	Solution equilibria and antitumor activities of pentamethylcyclopentadienyl rhodium complexes of picolinic acid and deferiprone. Journal of Coordination Chemistry, 2015, 68, 1583-1601.	0.8	22
192	Halfâ€Sandwich Ruthenium(II) Biotin Conjugates as Biological Vectors to Cancer Cells. Chemistry - A European Journal, 2015, 21, 5110-5117.	1.7	60
193	Speciation of metal-based nanomaterials in human serum characterized by capillary electrophoresis coupled to ICP-MS: a case study of gold nanoparticles. Metallomics, 2015, 7, 1364-1370.	1.0	55
194	Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Investigational New Drugs, 2015, 33, 835-847.	1.2	44
195	Influence of reducing agents on the cytotoxic activity of platinum(iv) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines. Metallomics, 2015, 7, 1078-1090.	1.0	34
196	Combination of Cadmium and High Cholesterol Levels as a Risk Factor for Heart Fibrosis. Toxicological Sciences, 2015, 145, 360-371.	1.4	20
197	Extravasation of Pt-based chemotherapeutics â€“ bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS). Metallomics, 2015, 7, 508-515.	1.0	27
198	Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. Chemical Science, 2015, 6, 2449-2456.	3.7	127

#	Article	IF	Citations
199	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(iv)-based anticancer agents. Metallomics, 2015, 7, 1256-1264.	1.0	42
200	Bis- and Tris(carboxylato)platinum(IV) Complexes with Mixed Am(m)ine Ligands in thetransPosition Exhibiting Exceptionally High Cytotoxicity. European Journal of Inorganic Chemistry, 2015, 2015, 1700-1708.	1.0	6
201	Complexes of N-hydroxyethyl-N-benzimidazolylmethylethylenediaminediacetic acid with group 12 metals and vanadiumâ€"Synthesis, structure and bioactivity of the vanadium complex. Journal of Inorganic Biochemistry, 2015, 147, 147-152.	1.5	15
202	The rearrangement of tosylated flavones to 1â€²-(alkylamino)aurones with primary amines. Tetrahedron, 2015, 71, 8953-8959.	1.0	12
203	Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups â€" A rational approach toward exploiting the platinum(IV) prodrug strategy. Journal of Inorganic Biochemistry, 2015, 153, 259-271.	1.5	24
204	River-derived humic substances as iron chelators in seawater. Marine Chemistry, 2015, 174, 85-93.	0.9	74
205	Vanadium(IV/V) complexes of Triapine and related thiosemicarbazones: Synthesis, solution equilibrium and bioactivity. Journal of Inorganic Biochemistry, 2015, 152, 62-73.	1.5	20
206	Comparative solution equilibrium studies on pentamethylcyclopentadienyl rhodium complexes of 2,2Ê¹-bipyridine and ethylenediamine and their interaction with human serum albumin. Journal of Inorganic Biochemistry, 2015, 152, 93-103.	1.5	23
207	Interaction of the anticancer gallium(III) complexes of 8-hydroxyquinoline and maltol with human serum proteins. Journal of Biological Inorganic Chemistry, 2015, 20, 77-88.	1.1	49
208	Organometallic complexes of (thio)allomaltol-based Mannich-products: Synthesis, stability and preliminary biological investigations. Journal of Organometallic Chemistry, 2015, 782, 69-76.	0.8	15
209	Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46. Molecular Cancer Therapeutics, 2014, 13, 2436-2449.	1.9	25
210	Platinum(IV) Complexes Featuring One or Two Axial Ferrocene Bearing Ligands â€" Synthesis, Characterization, and Cytotoxicity. European Journal of Inorganic Chemistry, 2014, 2014, 484-492.	1.0	28
211	Triapine and a More Potent Dimethyl Derivative Induce Endoplasmic Reticulum Stress in Cancer Cells. Molecular Pharmacology, 2014, 85, 451-459.	1.0	35
212	Solution equilibrium studies of anticancer ruthenium(II)-Î·6-p-cymene complexes of pyridinecarboxylic acids. Polyhedron, 2014, 67, 51-58.	1.0	13
213	Efficiently Detecting Metallodrugâ€"Protein Adducts: Ion Trap versus Timeâ€ofâ€Flight Mass Analyzers. ChemMedChem, 2014, 9, 1351-1355.	1.6	11
214	Guanidine platinum(II) complexes: synthesis, in vitro antitumor activity, and DNA interactions. Journal of Inorganic Biochemistry, 2014, 133, 33-39.	1.5	32
215	New method for the speciation of ruthenium-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks. Journal of Chromatography A, 2014, 1371, 168-176.	1.8	19
216	NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs. Chemical Science, 2014, 5, 3135-3143.	3.7	87

#	Article	IF	Citations
217	Microwave-assisted synthesis of N-heterocycle-based organometallics. Journal of Organometallic Chemistry, 2014, 772-773, 93-99.	0.8	14
218	Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation. Dalton Transactions, 2014, 43, 1096-1104.	1.6	35
219	A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer Prodrugs. Journal of Medicinal Chemistry, 2014, 57, 6751-6764.	2.9	49
220	NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science, 2014, 5, 2925-2932.	3.7	552
221	Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo. Journal of Membrane Biology, 2014, 247, 1239-1251.	1.0	12
222	Total Mercury in Sediments, Macrophytes, and Fish from a Shallow Steppe Lake in Eastern Austria. Chemistry and Biodiversity, 2014, 11, 1263-1275.	1.0	11
223	Can neutral analytes be concentrated by transient isotachophoresis in micellar electrokinetic chromatography and how much?. Journal of Chromatography A, 2014, 1345, 212-218.	1.8	8
224	Inductively coupled plasma mass spectrometry for metallodrug development: Albumin binding and serum distribution of cytotoxic cis- and trans-isomeric platinum(II) complexes. Journal of Inorganic Biochemistry, 2014, 137, 40-45.	1.5	26
225	Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: Synthesis, solution speciation and bioactivity. Journal of Inorganic Biochemistry, 2014, 134, 57-65.	1.5	73
226	Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. Dalton Transactions, 2014, 43, 9851.	1.6	7
227	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. Metallomics, 2014, 6, 1616-1625.	1.0	58
228	{Ru(CO)x}-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells. Polyhedron, 2014, 81, 227-237.	1.0	24
229	RutheniumII(Î·6-arene) Complexes of Thiourea Derivatives: Synthesis, Characterization and Urease Inhibition. Molecules, 2014, 19, 8080-8092.	1.7	27
230	A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2â€²-deoxyguanosine 5â€²-monophosphate (dGMP). Analytical and Bioanalytical Chemistry, 2013, 405, 6417-6424.	1.9	14
231	Platinum(IV) Complexes Featuring Axial (1, 4â€“‹sup›13‹/sup›C‹sub›2‹/sub›)Succinato Ligands â€“ Synthesis, Characterization, and Preliminary Âlnvestigations in Cancer Cell Lysates. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2013, 639, 1613-1620.	0.6	7
232	Copper(II) complexes with derivatives of pyrazole as potential antioxidant enzyme mimics. Medicinal Chemistry Research, 2013, 22, 2395-2402.	1.1	31
233	Solution equilibria of anticancer ruthenium(II)-(Î·6-p-cymene)-hydroxy(thio)pyr(id)one complexes: Impact of sulfur vs. oxygen donor systems on the speciation and bioactivity. Journal of Inorganic Biochemistry, 2013, 127, 161-168.	1.5	24
234	Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. Journal of Biological Inorganic Chemistry, 2013, 18, 249-260.	1.1	16

#	Article	IF	Citations
235	Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies. Journal of Biological Inorganic Chemistry, 2013, 18, 9-17.	1.1	125
236	Rhodium(Cp*) Compounds with Flavoneâ€derived Ligand Systems: Synthesis and Characterization. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2013, 639, 1648-1654.	0.6	17
237	New ruthenium(II)-arene complexes bearing hydrazides and the corresponding (thio)semicarbazones of 3- and 4-acetylpyridine: Synthesis, characterization, crystal structure determination and antiproliferative activity. Polyhedron, 2013, 61, 112-118.	1.0	15
238	Identification of the Structural Determinants for Anticancer Activity of a Ruthenium Arene Peptide Conjugate. Chemistry - A European Journal, 2013, 19, 9297-9307.	1.7	58
239	X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). Journal of Medicinal Chemistry, 2013, 56, 1182-1196.	2.9	49
240	Maleimide-functionalised platinum(iv) complexes as a synthetic platform for targeted drug delivery. Chemical Communications, 2013, 49, 2249.	2.2	84
241	Novel metal(ii) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents. Chemical Science, 2013, 4, 1837.	3.7	111
242	The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. European Journal of Cancer, 2013, 49, 3366-3375.	1.3	75
243	3-Hydroxyflavones vs. 3-hydroxyquinolinones: structureâ€“activity relationships and stability studies on Ru^{II}(arene) anticancer complexes with biologically active ligands. Dalton Transactions, 2013, 42, 6193-6202.	1.6	74
244	Theoretical Investigations and Density Functional Theory Based Quantitative Structureâ€“Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes. Journal of Medicinal Chemistry, 2013, 56, 330-344.	2.9	76
245	Natural organic matter and iron export from the Tanner Moor, Austria. Limnologica, 2013, 43, 239-244.	0.7	27
246	Bulky N,N-(Di)alkylethane-1,2-diamineplatinum(II) Compounds as Precursors for Generating Unsymmetrically Substituted Platinum(IV) Complexes. Inorganic Chemistry, 2013, 52, 8151-8162.	1.9	32
247	Metalâ€“Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. Organometallics, 2013, 32, 903-914.	1.1	57
248	Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. Chemical Communications, 2013, 49, 3348.	2.2	127
249	Am(m)ines Make the Difference: Organoruthenium Am(m)ine Complexes and Their Chemistry in Anticancer Drug Development. Chemistry - A European Journal, 2013, 19, 4308-4318.	1.7	31
250	p53 Increases Intra-Cellular Calcium Release by Transcriptional Regulation of Calcium Channel TRPC6 in GaQ3-Treated Cancer Cells. PLoS ONE, 2013, 8, e71016.	1.1	14
251	Influence of the Ï€-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes. Frontiers in Chemistry, 2013, 1, 27.	1.8	23
252	Waterâ€Soluble Cationic Derivatives of Indirubin, the Active Anticancer Component from Indigo naturalis. Chemistry and Biodiversity, 2012, 9, 2175-2185.	1.0	5

#	Article	IF	Citations
253	Novel Oximato-Bridged Platinum(II) Di- and Trimer(s): Synthetic, Structural, and in Vitro Anticancer Activity Studies. Inorganic Chemistry, 2012, 51, 7153-7163.	1.9	22
254	Capillary zone electrophoresis and capillary zone electrophoresisâ€“electrospray ionization mass spectrometry studies on the behavior of anticancer cis- and trans-[dihalidobis(2-propanone) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 650 697 T	1.8	16
255	Solid State Structural Variations in Copper(II) Complexes of Open-Chain and Macrocyclic Malonamide-Derived Ligands. Crystal Growth and Design, 2012, 12, 4388-4396.	1.4	4
256	Gallium compound GaQ₃â€•induced Ca²⁺ signalling triggers p53â€•dependent and â€•independent apoptosis in cancer cells. British Journal of Pharmacology, 2012, 166, 617-636.	2.7	45
257	Solid-phase synthesis of oxaliplatinâ€“TATpeptide bioconjugates. Dalton Transactions, 2012, 41, 3001-3005.	1.6	65
258	Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity. Journal of Inorganic Biochemistry, 2012, 113, 47-54.	1.5	38
259	A SAR Study of Novel Antiproliferative Ruthenium and Osmium Complexes with Quinoxalinone Ligands in Human Cancer Cell Lines. Journal of Medicinal Chemistry, 2012, 55, 3398-3413.	2.9	98
260	Organometallic Ruthenium and Osmium Compounds of Pyridinâ€2â€•and â€4â€•ones as Potential Anticancer Agents. Chemistry and Biodiversity, 2012, 9, 1718-1727.	1.0	17
261	Diamminetetrakis(carboxylato)platinum(IV) Complexes â€“ Synthesis, Characterization, and Cytotoxicity. Chemistry and Biodiversity, 2012, 9, 1840-1848.	1.0	11
262	Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugs. Chemical Communications, 2012, 48, 8559.	2.2	40
263	X-ray Absorption Spectroscopy of an Investigational Anticancer Gallium(III) Drug: Interaction with Serum Proteins, Elemental Distribution Pattern, and Coordination of the Compound in Tissue. Journal of Medicinal Chemistry, 2012, 55, 5601-5613.	2.9	36
264	Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. Chemical Communications, 2012, 48, 4839.	2.2	130
265	Unsymmetric Mono- and Dinuclear Platinum(IV) Complexes Featuring an Ethylene Glycol Moiety: Synthesis, Characterization, and Biological Activity. Journal of Medicinal Chemistry, 2012, 55, 11052-11061.	2.9	34
266	Nanoscale lignin particles as sources of dissolved iron to the ocean. Global Biogeochemical Cycles, 2012, 26, .	1.9	53
267	Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. Journal of Inorganic Biochemistry, 2012, 116, 180-187.	1.5	59
268	Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands. Journal of Inorganic Biochemistry, 2012, 117, 189-197.	1.5	53
269	<scp>l</scp>- and <scp>d</scp>-Proline Thiosemicarbazone Conjugates: Coordination Behavior in Solution and the Effect of Copper(II) Coordination on Their Antiproliferative Activity. Inorganic Chemistry, 2012, 51, 9309-9321.	1.9	64
270	Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex. Organometallics, 2012, 31, 5867-5874.	1.1	62

#	Article	IF	Citations
271	Application of ionic liquids for the removal of heavy metals from wastewater and activated sludge. Water Science and Technology, 2012, 65, 1765-1773.	1.2	67
272	Novel tetracarboxylatoplatinum(<scp>iv</scp>) complexes as carboplatin prodrugs. Dalton Transactions, 2012, 41, 14404-14415.	1.6	76
273	Structureâ€“Activity Relationships of Targeted Ru^{II}(Î·⁶-p-Cymene) Anticancer Complexes with Flavonol-Derived Ligands. Journal of Medicinal Chemistry, 2012, 55, 10512-10522.	2.9	132
274	Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs. Molecular Pharmacology, 2012, 81, 719-728.	1.0	54
275	Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules. Chemical Communications, 2012, 48, 1475-1477.	2.2	91
276	Complexâ€Formation Ability of Salicylaldehyde Thiosemicarbazone towards Zn^{II}, Cu^{II}, Fe^{II}, Fe^{III} and Ga^{III} Ions. European Journal of Inorganic Chemistry, 2012, 2012, 4036-4047.	1.0	44
277	Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. Hepatology, 2012, 55, 1112-1121.	3.6	52
278	Ionic Liquids as Extracting Agents for Heavy Metals. Separation Science and Technology, 2012, 47, 189-203.	1.3	155
279	Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues. Journal of Biological Inorganic Chemistry, 2012, 17, 699-708.	1.1	14
280	Impact of terminal dimethylation on the resistance profile of Î±-N-heterocyclic thiosemicarbazones. Biochemical Pharmacology, 2012, 83, 1623-1633.	2.0	16
281	Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 478-488.	1.7	89
282	Biomolecule binding vs. anticancer activity: Reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins. Journal of Inorganic Biochemistry, 2012, 108, 91-95.	1.5	53
283	Fragmentation methods on the balance: unambiguous topâ€“down mass spectrometric characterization of oxaliplatinâ€“ubiquitin binding sites. Analytical and Bioanalytical Chemistry, 2012, 402, 2655-2662.	1.9	39
284	Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. Journal of Biological Inorganic Chemistry, 2012, 17, 409-423.	1.1	120
285	Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. Journal of Biological Inorganic Chemistry, 2012, 17, 465-474.	1.1	51
286	Interaction of Triapine and related thiosemicarbazones with iron(iii)/(ii) and gallium(iii): a comparative solution equilibrium study. Dalton Transactions, 2011, 40, 5895.	1.6	65
287	Organometallic 3-(1H-Benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as Potential Anticancer Agents. Inorganic Chemistry, 2011, 50, 11715-11728.	1.9	32
288	Conjugation of Organoruthenium(II) 3-(1H-Benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and Indolo[3,2-d]benzazepines to Recombinant Human Serum Albumin: a Strategy To Enhance Cytotoxicity in Cancer Cells. Inorganic Chemistry, 2011, 50, 12669-12679.	1.9	56

#	Article	IF	Citations
289	Physicochemical Studies and Anticancer Potency of Ruthenium Î·⁶-p-Cymene Complexes Containing Antibacterial Quinolones. Organometallics, 2011, 30, 2506-2512.	1.1	105
290	Synthesis, Characterization, and Cytotoxic Activity of Novel Potentially pH-Sensitive Nonclassical Platinum(II) Complexes Featuring 1,3-Dihydroxyacetone Oxime Ligands. Inorganic Chemistry, 2011, 50, 10673-10681.	1.9	34
291	Rutheniumâ˜† and Osmiumâ˜†Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. Organometallics, 2011, 30, 273-283.	1.1	55
292	Mono-carboxylated diaminedichloridoplatinum(<scp>iv</scp>) complexes â€“ selective synthesis, characterization, and cytotoxicity. Dalton Transactions, 2011, 40, 8187-8192.	1.6	33
293	LCâ€“ and CZEâ€“ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(iii)] (KP1339) in mouse plasma. Metallomics, 2011, 3, 1049.	1.0	62
294	En Route to Osmium Analogues of KP1019: Synthesis, Structure, Spectroscopic Properties and Antiproliferative Activity of trans-[Os^{IV}Cl₄(Hazole)₂]. Inorganic Chemistry, 2011, 50, 7690-7697.	1.9	49
295	Anticancer Activity of Metal Complexes: Involvement of Redox Processes. Antioxidants and Redox Signaling, 2011, 15, 1085-1127.	2.5	420
296	Ionic liquids for extraction of metals and metal containing compounds from communal and industrial waste water. Water Research, 2011, 45, 4601-4614.	5.3	142
297	Microfluidic preparation of [18F]FE@SUPPY and [18F]FE@SUPPY:2 â€” comparison with conventional radiosyntheses. Nuclear Medicine and Biology, 2011, 38, 427-434.	0.3	25
298	Preparation and characterization of immobilized [A336][MTBA] in PVAâ€“alginate gel beads as novel solid-phase extractants for an efficient recovery of Hg (II) from aqueous solutions. Journal of Hazardous Materials, 2011, 196, 201-209.	6.5	45
299	Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. European Journal of Medicinal Chemistry, 2011, 46, 5456-5464.	2.6	70
300	Lectinâ€“Gd-Loaded Chitosan Hydrogel Nanoparticles: A New Biospecific Contrast Agent for MRI. Molecular Imaging and Biology, 2011, 13, 16-24.	1.3	11
301	Lectin Conjugates as Biospecific Contrast Agents for MRI. Coupling of Lycopersicon esculentum Agglutinin to Linear Water-Soluble DTPA-Loaded Oligomers. Molecular Imaging and Biology, 2011, 13, 432-442.	1.3	12
302	Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. Journal of Biological Inorganic Chemistry, 2011, 16, 1205-1215.	1.1	23
303	A polymer inclusion membrane based on the ionic liquid trihexyl(tetradecyl)phosphonium chloride and PVC for solidâ€“liquid extraction of Zn(II) from hydrochloric acid solution. Monatshefte FÃ¼r Chemie, 2011, 142, 769-772.	0.9	39
304	Interactions of the carrier ligands of antidiabetic metal complexes with human serum albumin: A combined spectroscopic and separation approach with molecular modeling studies. Bioorganic and Medicinal Chemistry, 2011, 19, 4202-4210.	1.4	23
305	Hydroxy and ether functionalized dithiolanes: Models for the active site of the [FeFe] hydrogenase. Journal of Organometallic Chemistry, 2011, 696, 1084-1088.	0.8	14
306	Pyrone derivatives and metals: From natural products to metal-based drugs. Journal of Organometallic Chemistry, 2011, 696, 999-1010.	0.8	86

#	Article	IF	Citations
307	A quantitative structureâ€“activity approach for lipophilicity estimation of antitumor complexes of different metals using microemulsion electrokinetic chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 409-413.	1.4	17
308	Synthesis, structures and in vitro cytotoxicity of some cationic cis-platinum(II) complexes containing chelating thiocarbamates. Journal of Inorganic Biochemistry, 2011, 105, 462-466.	1.5	12
309	Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. Journal of Inorganic Biochemistry, 2011, 105, 46-51.	1.5	107
310	From hydrolytically labile to hydrolytically stable Rullâ€“arene anticancer complexes with carbohydrate-derived co-ligands. Journal of Inorganic Biochemistry, 2011, 105, 224-231.	1.5	65
311	Strategies for the covalent conjugation of a bifunctional chelating agent to albumin: Synthesis and characterization of potential MRI contrast agents. Journal of Inorganic Biochemistry, 2011, 105, 250-255.	1.5	9
312	Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?. Journal of Inorganic Biochemistry, 2011, 105, 709-717.	1.5	35
313	X-ray structure and cytotoxic activity of a picolinate ruthenium(II)-arene complex. Journal of the Serbian Chemical Society, 2011, 76, 53-61.	0.4	23
314	Osmium(ii)â€“versus ruthenium(ii)â€“arene carbohydrate-based anticancer compounds: similarities and differences. Dalton Transactions, 2010, 39, 7345.	1.6	88
315	Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. Journal of Biological Inorganic Chemistry, 2010, 15, 677-688.	1.1	86
316	Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. Journal of Biological Inorganic Chemistry, 2010, 15, 737-748.	1.1	150
317	Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. Journal of Biological Inorganic Chemistry, 2010, 15, 903-918.	1.1	51
318	Relevance of peat-draining rivers for the riverine input of dissolved iron into the ocean. Science of the Total Environment, 2010, 408, 2402-2408.	3.9	86
319	Comparative Solution Equilibrium Study of the Interactions of Copper(II), Iron(II) and Zinc(II) with Triapine (3â€Aminopyridineâ€2â€carbaldehyde Thiosemicarbazone) and Related Ligands. European Journal of Inorganic Chemistry, 2010, 2010, 1717-1728.	1.0	74
320	Synthetic and Electrochemical Studies of [2Fe2S] Complexes Containing a 4â€Aminoâ€1,2â€dithiolaneâ€4â€carboxylic Acid Moiety. European Journal of Inorganic Chemistry, 2010, 2010, 5079-5086.	1.0	9
321	The first example of MEEKCâ€ICPâ€MS coupling and its application for the analysis of anticancer platinum complexes. Electrophoresis, 2010, 31, 1144-1150.	1.3	45
322	Transport and separation of iron(III) from nickel(II) with the ionic liquid trihexyl(tetradecyl)phosphonium chloride. Separation and Purification Technology, 2010, 72, 56-60.	3.9	86
323	New platinumâ€“oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. Journal of Inorganic Biochemistry, 2010, 104, 799-814.	1.5	50
324	Synthesis and crystal structure of N-phenyl-Nâ€²-(pyridin-2-ylmethyl)-S-methyl-thiouronium iodide. Journal of Molecular Structure, 2010, 965, 50-55.	1.8	2

#	Article	IF	Citations
325	Mannich products of kojic acid and N-heterocycles and their Ru(II)â€“arene complexes: Synthesis, characterization and stability. Journal of Organometallic Chemistry, 2010, 695, 875-881.	0.8	26
326	Ruthenium(II)â€“arene complexes with functionalized pyridines: Synthesis, characterization and cytotoxic activity. European Journal of Medicinal Chemistry, 2010, 45, 1051-1058.	2.6	74
327	Tetrachloroferrate containing ionic liquids: Magnetic- and aggregation behavior. Inorganic Chemistry Communication, 2010, 13, 1485-1488.	1.8	31
328	Phosphonium and Ammonium Ionic Liquids with Aromatic Anions: Synthesis, Properties, and Platinum Extraction. Australian Journal of Chemistry, 2010, 63, 511.	0.5	86
329	Is the Reactivity of M(II)â^'Arene Complexes of 3-Hydroxy-2(1H)-pyridones to Biomolecules the Anticancer Activity Determining Parameter?. Inorganic Chemistry, 2010, 49, 7953-7963.	1.9	101
330	{(1R,2R,4R)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically Pure Oxaliplatin Derivative Showing Improved Anticancer Activity in Vivo. Journal of Medicinal Chemistry, 2010, 53, 7356-7364.	2.9	51
331	Highly Cytotoxic Copper(II) Complexes with Modified Paullone Ligands. Inorganic Chemistry, 2010, 49, 302-311.	1.9	48
332	Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II)â€“(Î·6-Arene) Complexes. Australian Journal of Chemistry, 2010, 63, 1521.	0.5	33
333	Novel Cis- and Trans-Configured Bis(oxime)platinum(II) Complexes: Synthesis, Characterization, and Cytotoxic Activity. Inorganic Chemistry, 2010, 49, 5669-5678.	1.9	49
334	Structureâ^'Activity Relationships of Highly Cytotoxic Copper(II) Complexes with Modified Indolo[3,2-c]quinoline Ligands. Inorganic Chemistry, 2010, 49, 11084-11095.	1.9	55
335	Fluorescence properties and cellular distribution of the investigational anticancer drugTriapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(ii) complex. Dalton Transactions, 2010, 39, 704-706.	1.6	77
336	Synthesis and structures of novel 1-methylcytosinato-bridged (ethylenediamine)platinum(ii) and platinum(iii) dinuclear complexes. Dalton Transactions, 2010, 39, 3633.	1.6	18
337	The influence of electroporation on cytotoxicity of anticancer ruthenium(III) complex KP1339 in vitro and in vivo. Anticancer Research, 2010, 30, 2055-63.	0.5	14
338	DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media. Biochemical Pharmacology, 2009, 77, 364-374.	2.0	76
339	Maltolâ€Derived Rutheniumâ€“Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligandâ€“Metal Bond Stability on Anticancer Activity In Vitro. Chemistry - A European Journal, 2009, 15, 12283-12291.	1.7	111
340	New Insights into the Chemistry of the Antineoplastic Lanthanum Complex Tris(1,10â€phenanthroline)tris(thiocyanatoâ€Î^κN)lanthanum(III) (KP772) and Its Interaction with Biomolecules. European Journal of Inorganic Chemistry, 2009, 2009, 4282-4287.	1.0	33
341	Biodistribution of antiâ€diabetic Zn(II) complexes in human serum and in vitro proteinâ€binding studies by means of CZEâ€“ICPâ€MS. Electrophoresis, 2009, 30, 4075-4082.	1.3	24
342	A Novel Cytotoxic Cerium Complex: Aquatrichloridobis(1,10â€phenanthroline)cerium(III) (KP776). Synthesis, Characterization, Behavior in H₂O, Binding towards Biomolecules, and Antiproliferative Activity. Chemistry and Biodiversity, 2009, 6, 2153-2165.	1.0	21

#	Article	IF	Citations
343	Investigation of amino acid containing [FeFe] hydrogenase models concerning pendant base effects. Journal of Inorganic Biochemistry, 2009, 103, 1236-1244.	1.5	18
344	Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety. Journal of Organometallic Chemistry, 2009, 694, 922-929.	0.8	64
345	A one step/one pot synthesis of N,N-bis(phosphonomethyl)amino acids and their effects on adipogenic and osteogenic differentiation of human mesenchymal stem cells. Bioorganic and Medicinal Chemistry, 2009, 17, 3388-3393.	1.4	10
346	Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta. Organometallics, 2009, 28, 1165-1172.	1.1	79
347	[Os^{IV}Cl₅(Hazole)]^{â^'} Complexes: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. Inorganic Chemistry, 2009, 48, 10737-10747.	1.9	21
348	Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity. Journal of Medicinal Chemistry, 2009, 52, 916-925.	2.9	168
349	From Pyrone to Thiopyrone Ligandsâ^'Rendering Maltol-Derived Ruthenium(II)â^'Arene Complexes That Are Anticancer Active in Vitro. Organometallics, 2009, 28, 4249-4251.	1.1	85
350	Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation. Journal of Medicinal Chemistry, 2009, 52, 5032-5043.	2.9	143
351	Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on thein VitroAntitumor Activity of Polynuclear Organometallic Compounds. Organometallics, 2009, 28, 6260-6265.	1.1	92
352	Synthesis and biological studies of some gold(I) complexes containing functionalised alkynes. Dalton Transactions, 2009, , 10841.	1.6	56
353	Synthesis and structures of palladium(II) and platinum(II) complexes containing heterocyclic thiolate ligands formed by cycloaddition reactions of coordinated azides. Canadian Journal of Chemistry, 2009, 87, 146-150.	0.6	13
354	Synthesis, X-ray diffraction structure, spectroscopic properties and antiproliferative activity of a novel ruthenium complex with constitutional similarity to cisplatin. Dalton Transactions, 2009, , 3334.	1.6	27
355	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. Journal of Analytical Atomic Spectrometry, 2009, 24, 51-61.	1.6	100
356	Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anti-Cancer Drugs, 2009, 20, 97-103.	0.7	214
357	The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. Melanoma Research, 2009, 19, 283-293.	0.6	56
358	5-Hydroxy-2-methyl-4H-pyran-4-one. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o437-o437.	0.2	2
359	Greener synthesis of new ammonium ionic liquids and their potential as extracting agents. Tetrahedron Letters, 2008, 49, 2782-2785.	0.7	104
360	In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrateâ€Based Ligands. Chemistry - A European Journal, 2008, 14, 9046-9057.	1.7	111

#	Article	IF	Citations
361	Spontaneous Resolution of a Tripleâ€Stranded Dinickel(II) Helicate Generated via Intermolecular Transamination Reaction ofSâ€Methylisothiocarbohydrazide in the Presence of Ni²⁺. European Journal of Inorganic Chemistry, 2008, 2008, 4140-4145.	1.0	5
362	Capillary electrophoresis hyphenated to inductively coupled plasmaâ€mass spectrometry: A novel approach for the analysis of anticancer metallodrugs in human serum and plasma. Electrophoresis, 2008, 29, 2224-2232.	1.3	86
363	Editorial: Topics in Bioinorganic Chemistry. Chemistry and Biodiversity, 2008, 5, 1435-1436.	1.0	0
364	Hydrolysis and Cytotoxic Properties of Osmium(II)/(III)-DMSO-Azole Complexes. Short Communication. Chemistry and Biodiversity, 2008, 5, 1588-1593.	1.0	12
365	Elucidation of the Interactions of an Anticancer Ruthenium Complex in Clinical Trials with Biomolecules Utilizing Capillary Electrophoresis Hyphenated to Inductively Coupled Plasmaâ€Mass Spectrometry. Short Communication. Chemistry and Biodiversity, 2008, 5, 1609-1614.	1.0	33
366	Phosphiteâ€Derivatized Rutheniumâ€Carbohydrate Complexes in the Catalytic Hydration of Nitriles. Short Communication. Chemistry and Biodiversity, 2008, 5, 1640-1644.	1.0	22
367	The Hydration of Chloroacetonitriles Catalyzed by Monoâ€and Dinuclear Ru^{II}â€and Os^{II}â€Arene Complexes. Chemistry and Biodiversity, 2008, 5, 2060-2066.	1.0	21
368	KP1019, A New Redoxâ€Active Anticancer Agent â€“ Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. Chemistry and Biodiversity, 2008, 5, 2140-2155.	1.0	732
369	Novel Endothallâ€Containing Platinum(IV) Complexes: Synthesis, Characterization, and Cytotoxic Activity. Chemistry and Biodiversity, 2008, 5, 2160-2170.	1.0	38
370	Modifying the structure of dinuclear ruthenium complexes with antitumor activity. Applied Organometallic Chemistry, 2008, 22, 326-332.	1.7	45
371	Capillary electrophoretic assay for the stability of tris(8-quinolinolato)gallium(III) in tablet formulations. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 218-222.	1.4	13
372	Studies on the reactivity of organometallic Ruâ€“, Rhâ€“ and Osâ€“pta complexes with DNA model compounds. Journal of Inorganic Biochemistry, 2008, 102, 1066-1076.	1.5	101
373	CZEâ€“ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. Journal of Inorganic Biochemistry, 2008, 102, 1060-1065.	1.5	92
374	Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(Î·6-p-cymene)Cl2(pta)]. Journal of Inorganic Biochemistry, 2008, 102, 1743-1748.	1.5	108
375	Synthesis, structures and in vitro cytotoxicity of some platinum(II) complexes containing thiocarbamate esters. Journal of Inorganic Biochemistry, 2008, 102, 2067-2071.	1.5	29
376	Novel bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. Journal of Inorganic Biochemistry, 2008, 102, 2072-2077.	1.5	41
377	Toward high-throughput monitoring of metallodrugâ€“protein interaction using capillary electrophoresis in chemically modified capillaries. Analytical Biochemistry, 2008, 379, 216-218.	1.1	18
378	Application of capillary electrophoresisâ€“inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins. Journal of Chromatography A, 2008, 1192, 323-326.	1.8	44

#	Article	IF	Citations
379	Analysis of quaternary ammonium and phosphonium ionic liquids by reversed-phase high-performance liquid chromatography with charged aerosol detection and unified calibration. Journal of Chromatography A, 2008, 1209, 179-187.	1.8	39
380	Methyl-substituted trans-1,2-cyclohexanediamines as new ligands for oxaliplatin-type complexes. Tetrahedron, 2008, 64, 137-146.	1.0	10
381	Electron-transfer activated metal-based anticancer drugs. Inorganica Chimica Acta, 2008, 361, 1569-1583.	1.2	177
382	Synthesis and structural peculiarities of gallium Complexes with novel paullone derivatives. Open Chemistry, 2008, 6, 340-346.	1.0	5
383	An Electrochemical Study of Antineoplastic Gallium, Iron and Ruthenium Complexes with Redox Noninnocent Î±-N-Heterocyclic Chalcogensemicarbazones. Inorganic Chemistry, 2008, 47, 11032-11047.	1.9	57
384	Computational Electrochemistry of Ruthenium Anticancer Agents. Unprecedented Benchmarking of Implicit Solvation Methods. Journal of Chemical Theory and Computation, 2008, 4, 499-506.	2.3	31
385	Water-Soluble Mixed-Ligand Ruthenium(II) and Osmium(II) Arene Complexes with High Antiproliferative Activity. Organometallics, 2008, 27, 6587-6595.	1.1	71
386	Preparation and first evaluation of [18F]FE@SUPPY: a new PET tracer for the adenosine A3 receptor. Nuclear Medicine and Biology, 2008, 35, 61-66.	0.3	28
387	Resistance against novel anticancer metal compounds: Differences and similarities. Drug Resistance Updates, 2008, 11, 1-16.	6.5	201
388	Synthesis and Reactivity of the Aquation Product of the Antitumor Complex trans-[Ru^{III}Cl₄(indazole)₂]^{â^'}. Inorganic Chemistry, 2008, 47, 6513-6523.	1.9	50
389	Unprecedented twofold intramolecular hydroamination in diam(m)ine-dicarboxylatodichloridoplatinum(iv) complexes â€“ ethane-1,2-diaminevs.ammine ligands. Chemical Communications, 2008, , 1091-1093.	2.2	4
390	Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity In Vitro of Novel Osmium(III) Complexes with Azole Heterocycles. Inorganic Chemistry, 2008, 47, 7338-7347.	1.9	32
391	Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium(II)Arene Compounds. Organometallics, 2008, 27, 2405-2407.	1.1	180
392	High Resolution Mass Spectrometry for Studying the Interactions of Cisplatin with Oligonucleotides. Inorganic Chemistry, 2008, 47, 10626-10633.	1.9	63
393	Carbohydrate-Metal Complexes and their Potential as Anticancer Agents. Current Medicinal Chemistry, 2008, 15, 2574-2591.	1.2	160
394	Reversion of Structure-Activity Relationships of Antitumor Platinum Complexes by Acetoxime but Not Hydroxylamine Ligands. Molecular Pharmacology, 2007, 71, 357-365.	1.0	53
395	Searching for the Magic Bullet: Anticancer Platinum Drugs Which Can Be Accumulated or Activated in the Tumor Tissue. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 55-73.	0.9	136
396	Nanopartikel zur Diagnose von BlutgefÃÄŸerkrankungen. Nachrichten Aus Der Chemie, 2007, 55, 842-846.	0.0	1

#	Article	IF	Citations
397	18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers. Nuclear Medicine and Biology, 2007, 34, 1019-1028.	0.3	20
398	Mass spectrometric analysis of ubiquitinâ€“platinum interactions of leading anticancer drugs: MALDI versus ESI. Journal of Analytical Atomic Spectrometry, 2007, 22, 960-967.	1.6	89
399	Gallium(III) and Iron(III) Complexes of Î±-N-Heterocyclic Thiosemicarbazones:â€‰ Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase. Journal of Medicinal Chemistry, 2007, 50, 1254-1265.	2.9	145
400	Highly Antiproliferative Ruthenium(II) and Osmium(II) Arene Complexes with Paullone-Derived Ligands. Organometallics, 2007, 26, 6643-6652.	1.1	134
401	Two new â€œoniumâ€•fluorosilicates, the products of interaction of fluorosilicic acid with 12-membered macrocycles: structures and spectroscopic properties. Dalton Transactions, 2007, , 2915-2924.	1.6	17
402	Tuning the hydrophobicity of ruthenium(ii)â€“arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Transactions, 2007, , 5065.	1.6	131
403	First Example of the Solid-State Thermal Cyclometalation of Ligated Benzophenone Imine Giving Novel Luminescent Platinum(II) Species. Inorganic Chemistry, 2007, 46, 4469-4482.	1.9	44
404	Novel Di- and Tetracarboxylatoplatinum(IV) Complexes. Synthesis, Characterization, Cytotoxic Activity, and DNA Platination. Journal of Medicinal Chemistry, 2007, 50, 6692-6699.	2.9	88
405	Osmium NAMI-A Analogues:Â Synthesis, Structural and Spectroscopic Characterization, and Antiproliferative Properties. Inorganic Chemistry, 2007, 46, 5023-5033.	1.9	66
406	The First Ruthenium-Based Paullones:â€‰ Syntheses, X-ray Diffraction Structures, and Spectroscopic and Antiproliferative Properties in Vitro. Inorganic Chemistry, 2007, 46, 3645-3656.	1.9	40
407	Structureâ^'Activity Relationships for NAMI-A-type Complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4-triazole, and 1-Methyl-1,2,4-triazole):Â Aquation, Redox Properties, Protein Binding, and Antiproliferative Activity. Journal of Medicinal Chemistry, 2007, 50, 2185-2193.	2.9	206
408	Metal-Based Paullones as Putative CDK Inhibitors for Antitumor Chemotherapy. Journal of Medicinal Chemistry, 2007, 50, 6343-6355.	2.9	86
409	The Complexes [OsCl2(azole)2(dmso)2] and [OsCl2(azole)(dmso)3]: Synthesis, Structure, Spectroscopic Properties and Catalytic Hydration of Chloronitriles. European Journal of Inorganic Chemistry, 2007, 2007, 400-411.	1.0	43
410	Ruthenium(II) Complexes of Thiosemicarbazones: The First Water-Soluble Complex with pH-Dependent Antiproliferative Activity. European Journal of Inorganic Chemistry, 2007, 2007, 2870-2878.	1.0	43
411	Synthesis, Structure, Protolytic Properties, Alkylating and Cytotoxic Activity of Novel Platinum(II) and Palladium(II) Complexes with Pyrazole-Derived Ligands. European Journal of Inorganic Chemistry, 2007, 2007, 3728-3735.	1.0	32
412	Probing the stability of serum proteinâ€“ruthenium(III) drug adducts in the presence of extracellular reductants using CE. Electrophoresis, 2007, 28, 2235-2240.	1.3	46
413	CE in anticancer metallodrug research â€“ an update. Electrophoresis, 2007, 28, 3436-3446.	1.3	59
414	A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. ChemMedChem, 2007, 2, 505-514.	1.6	49

#	Article	IF	Citations
415	Application of micellar and microemulsion electrokinetic chromatography for characterization of gallium(III) complexes of pharmaceutical significance. Journal of Separation Science, 2007, 30, 399-406.	1.3	17
416	Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis. Journal of Chromatography A, 2007, 1155, 218-221.	1.8	33
417	Capillary electrophoresis of metal-based drugs. Analytical Biochemistry, 2007, 369, 1-7.	1.1	22
418	Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. Journal of Inorganic Biochemistry, 2007, 101, 1946-1957.	1.5	71
419	Antitumour metal compounds: more than theme and variations. Dalton Transactions, 2007, , 183-194.	1.6	767
420	Redox behavior of tumor-inhibiting ruthenium(iii) complexes and effects of physiological reductants on their binding to GMP. Dalton Transactions, 2006, , 1796.	1.6	197
421	DNA Interactions of pH-Sensitive, Antitumor Bis(aminoalcohol)dichloroplatinum(II) Complexesâ€‚â€¡. Biochemistry, 2006, 45, 14817-14825.	1.2	27
422	The First Metal-Based Paullone Derivative with High Antiproliferative Activity in Vitro. Inorganic Chemistry, 2006, 45, 1945-1950.	1.9	46
423	Interactions of Antitumor Metallodrugs with Serum Proteins:Â Advances in Characterization Using Modern Analytical Methodology. Chemical Reviews, 2006, 106, 2224-2248.	23.0	570
424	NCA nucleophilic radiofluorination on substituted benzaldehydes for the preparation of [18F]fluorinated aromatic amino acids. Applied Radiation and Isotopes, 2006, 64, 355-359.	0.7	5
425	Determination of cisplatin and its hydrolytic metabolite in human serum by capillary electrophoresis techniques. Journal of Chromatography A, 2006, 1106, 75-79.	1.8	62
426	Electrospray ionization mass spectrometric study on the coordination behavior of dacarbazine towards transition metal ions. Polyhedron, 2006, 25, 1971-1978.	1.0	6
427	From bench to bedside â€“ preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). Journal of Inorganic Biochemistry, 2006, 100, 891-904.	1.5	882
428	Preclinical characterization of anticancer gallium(III) complexes: Solubility, stability, lipophilicity and binding to serum proteins. Journal of Inorganic Biochemistry, 2006, 100, 1819-1826.	1.5	100
429	Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochemical Pharmacology, 2006, 71, 426-440.	2.0	124
430	An Entry to Novel Platinum Complexes: Carboxylation of Dihydroxoplatinum(IV) Complexes with Succinic Anhydride and Subsequent Derivatization. European Journal of Inorganic Chemistry, 2006, 2006, 2612-2617.	1.0	77
431	Bis(2-amino alcohol-Î²N)dicarboxylatoplatinum(II) Complexes â€“ Elegant Synthesis via Ring-Opening of Bis(2-amino alcoholato-Î²2N,O)platinum(II) Species with Dicarboxylic Acids. European Journal of Inorganic Chemistry, 2006, 2006, 2476-2483.	1.0	14
432	Synthesis and Characterization of [(1R,2R)-trans-Diaminocyclohexane]platinum(II) Coordinated to Sulfur and Selenium Amino Acids. European Journal of Inorganic Chemistry, 2006, 2006, 3746-3752.	1.0	29

#	Article	IF	Citations
433	Platinum group metallodrug-protein binding studies by capillary electrophoresis â€“ inductively coupled plasma-mass spectrometry: A further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. Electrophoresis, 2006, 27, 1128-1135.	1.3	100
434	Bis- and tris-bicyclophosphites of d-glucofuranoside. Unexpected catalysis of P(III/V)-oxidation by triethylamine. Tetrahedron, 2005, 61, 10943-10950.	1.0	6
435	Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis. Analytical Biochemistry, 2005, 341, 326-333.	1.1	85
436	Synthesis and structure-activity relationships of mono- and dialkyl-substituted oxaliplatin derivatives. European Journal of Medicinal Chemistry, 2005, 40, 1149-1155.	2.6	43
437	1,1'-Bis(oxazolin-2-yl)ferrocenes: An Investigation of Their Complexation Behavior toward [Pd(?3-allyl)Cl]2. European Journal of Inorganic Chemistry, 2005, 2005, 1589-1600.	1.0	14
438	Analysis of anticancer platinum(II)-complexes by microemulsion electrokinetic chromatography: Separation of diastereomers and estimation of octanol-water partition coefficients. Electrophoresis, 2005, 26, 878-884.	1.3	54
439	Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method. Journal of Separation Science, 2005, 28, 121-127.	1.3	80
440	Cisplatin Damage: Are DNA Repair Proteins Saviors or Traitors to the Cell?. ChemBioChem, 2005, 6, 1157-1166.	1.3	94
441	Design, synthesis, physical and chemical characterisation, and biological interactions of lectin-targeted latex nanoparticles bearing Gdâ€“DTPA chelates: an exploration of magnetic resonance molecular imaging (MRMI). Histochemistry and Cell Biology, 2005, 123, 283-301.	0.8	33
442	On the Coordination Properties of New Bicyclophosphite-Carbohydrates. Monatshefte FÃ¼r Chemie, 2005, 136, 137-146.	0.9	2
443	Synthesis, Cytotoxicity, and Structure-Activity Relationships of New Oxaliplatin Derivatives. Monatshefte FÃ¼r Chemie, 2005, 136, 693-700.	0.9	16
444	Synthesis andin vitroAntitumor Potency of (Cyclohexane-1,2-Diamine)Platinum(II) Complexes with Aminotris(Methylenephosphonic Acid) as Bone-Seeking Ligand. Bioinorganic Chemistry and Applications, 2005, 3, 179-190.	1.8	8
445	Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Current Medicinal Chemistry, 2005, 12, 2075-2094.	1.2	657
446	Reactions of Potent Antitumor Complex trans-[RuIIICl4(indazole)2]- with a DNA-Relevant Nucleobase and Thioethers:â€‰ Insight into Biological Action. Inorganic Chemistry, 2005, 44, 122-132.	1.9	59
447	Isomeric [RuCl2(dmso)2(indazole)2] complexes: ruthenium(ii)-mediated coupling reaction of acetonitrile with 1H-indazole. Dalton Transactions, 2005, , 2355.	1.6	29
448	Tumour-inhibiting platinum(ii) complexes with aminoalcohol ligands: biologically important transformations studied by micellar electrokinetic chromatography, nuclear magnetic resonance spectroscopy and mass spectrometry. Analyst, The, 2005, 130, 1383.	1.7	23
449	Redox-Active Antineoplastic Ruthenium Complexes with Indazole:Â Correlation of in Vitro Potency and Reduction Potential. Journal of Medicinal Chemistry, 2005, 48, 2831-2837.	2.9	156
450	The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Letters, 2005, 226, 115-121.	3.2	111

#	Article	IF	Citations
451	Tuning of Redox Properties for the Design of Ruthenium Anticancer Drugs:Â Part 2. Syntheses, Crystal Structures, and Electrochemistry of Potentially Antitumor [RuIII/IICl6-n(Azole)n]z(n= 3, 4, 6) Complexesâ€. Inorganic Chemistry, 2005, 44, 6704-6716.	1.9	77
452	Gallium in Cancer Treatment. Current Topics in Medicinal Chemistry, 2004, 4, 1575-1583.	1.0	138
453	Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: Characterization of interactions between Pt(II) complexes and human serum albumin. Electrophoresis, 2004, 25, 1988-1995.	1.3	125
454	Analysis of Platinum Adducts with DNA Nucleotides and Nucleosides by Capillary Electrophoresis Coupled to ESI-MS: Indications of Guanosine 5â€²-Monophosphate O6-N7 Chelation. ChemBioChem, 2004, 5, 1543-1549.	1.3	52
455	Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato-Iº2N,O)platinum(II) â€“ a representative of novel pH sensitive anticancer platinum complexes. Inorganica Chimica Acta, 2004, 357, 3237-3244.	1.2	46
456	Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. European Journal of Medicinal Chemistry, 2004, 39, 707-714.	2.6	51
457	Tuning of Redox Potentials for the Design of Ruthenium Anticancer Drugs â^' an Electrochemical Study of [trans-RuCl4L(DMSO)]-and [trans-RuCl4L2]-Complexes, where L = Imidazole, 1,2,4-Triazole, Indazole. Inorganic Chemistry, 2004, 43, 7083-7093.	1.9	159
458	Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. Journal of Analytical Atomic Spectrometry, 2004, 19, 46.	1.6	183
459	Gallium and Other Main Group Metal Compounds as Antitumor Agents. , 2004, , 425-462.		45
460	The Effect of Cytoprotective Agents in Platinum Anticancer Therapy. , 2004, , 179-208.		8
461	Gallium and other main group metal compounds as antitumor agents. Metal Ions in Biological Systems, 2004, 42, 425-62.	0.4	12
462	Capillary electrophoresis in anti-cancer metallodrug research: Advances and future challenges. Electrophoresis, 2003, 24, 2023-2037.	1.3	55
463	Tumor-inhibiting platinum(II) complexes with aminoalcohol ligands: Comparison of the mode of action by capillary electrophoresis and electrospray ionization-mass spectrometry. Electrophoresis, 2003, 24, 2038-2044.	1.3	37
464	Radiosynthesis of 3-(2â€²-[18F]fluoro)-flumazenil ([18F]FFMZ). Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 1229-1240.	0.5	12
465	Crystallographic report: Crystal structure of 1-bromo-1?-[(2S)-N-(1-hydroxy-3-methylbutane-2-yl)]-ferroceneamide. Applied Organometallic Chemistry, 2003, 17, 723-724.	1.7	0
466	Synthesis, X-ray Diffraction Structures, Spectroscopic Properties, and in vitro Antitumor Activity of Isomeric (1H-1,2,4-Triazole)Ru(III) Complexes. Inorganic Chemistry, 2003, 42, 6024-6031.	1.9	94
467	Amidines Derived from Pt(IV)-Mediated Nitrileâ^'Amino Alcohol Coupling and Their Zn(II)-Catalyzed Conversion into Oxazolines. Inorganic Chemistry, 2003, 42, 2805-2813.	1.9	26
468	Synthesis, Characterization, and in Vitro Antitumor Activity of Osteotropic Diam(m)ineplatinum(II) Complexes Bearing aN,N-Bis(phosphonomethyl)glycine Ligandâ€. Journal of Medicinal Chemistry, 2003, 46, 4946-4951.	2.9	58

#	Article	IF	Citations
469	Synthesis, crystal structures, and electrospray ionisation mass spectrometry investigations of ether- and thioether-substituted ferrocenes. Dalton Transactions, 2003, , 3098.	1.6	8
470	Novel glucose-ferrocenyl derivatives: synthesis and properties. New Journal of Chemistry, 2002, 26, 671-673.	1.4	28
471	Platinum(iv)-mediated coupling of dione monoximes and nitriles: a novel reactivity pattern of the classic oxime-based chelating ligands. New Journal of Chemistry, 2002, 26, 1085-1091.	1.4	34
472	Application of capillary electrophoresis-mass spectrometry for the investigation of the binding behavior of oxaliplatin to 5â€™-GMP in the presence of the sulfur-containing amino acid L-methionine. Electrophoresis, 2002, 23, 74.	1.3	32
473	Gallium in cancer treatment. Critical Reviews in Oncology/Hematology, 2002, 42, 283-296.	2.0	216
474	Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine 4N-dimethylthiosemicarbazone. Journal of Inorganic Biochemistry, 2002, 91, 298-305.	1.5	97
475	Synthesis of ferrocenylglucose phosphonite and bisphosphinite: Pd(II) and Pt(II) complexes, Pd-catalyzed allylic alkylation. Tetrahedron, 2002, 58, 8489-8492.	1.0	23
476	Reaction of (SP-4-2)-dichlorobis(2-hydroxyethylamine)platinum(II) with 5â€²-GMP under simulated physiological conditions, a CZE-ESI-MS study. Inorganica Chimica Acta, 2002, 339, 9-13.	1.2	21
477	Capillary electrophoresis of platinum-group elements. Journal of Chromatography A, 2002, 945, 25-44.	1.8	54
478	Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS. Journal of Biological Inorganic Chemistry, 2001, 6, 292-299.	1.1	87
479	Capillary electrophoretic study of carboplatin and analogues with nucleoside monophosphates, di- and trinucleotides. Journal of Inorganic Biochemistry, 2001, 83, 181-186.	1.5	22
480	Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5â€²-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry. Journal of Inorganic Biochemistry, 2001, 86, 691-698.	1.5	77
481	Investigations into the interaction between tumor-inhibiting ruthenium(III) complexes and nucleotides by capillary electrophoresis. Biomedical Applications, 2001, 759, 81-89.	1.7	31
482	Reaction monitoring of platinum(II) complex-5â€²-guanosine monophosphate adduct formation by ion exchange liquid chromatography/electrospray ionization mass spectrometry. Journal of Mass Spectrometry, 2001, 36, 742-753.	0.7	16
483	[RuCl3ind3] and [RuCl2ind4]: Two New Ruthenium Complexes derived from the Tumor-inhibiting RuIII Compound HInd (OC-6-11)-[RuCl4ind2] (indâ€Š=â€Šindazole). Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2001, 627, 261-265.	0.6	12
484	Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media. Journal of Biological Inorganic Chemistry, 2001, 6, 435-445.	1.1	76
485	Kinetics of binding properties of 5â€²-GMP with cisplatin under simulated physiological conditions by capillary electrophoresis. Biomedical Applications, 2000, 745, 211-219.	1.7	34
486	Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III). Journal of Inorganic Biochemistry, 2000, 78, 341-346.	1.5	98

#	Article	IF	Citations
487	Is reduction required for antitumour activity of platinum(IV) compounds? Characterisation of a platinum(IV)â€“nucleotide adduct [enPt(OCOCH3)3(5â€²-GMP)] by NMR spectroscopy and ESI-MS. Inorganica Chimica Acta, 2000, 300-302, 783-789.	1.2	43
488	Solvolysis of the Tumor-Inhibiting Ru(III)-Complex trans-Tetrachlorobis(Indazole)Ruthenate(III). Metal-Based Drugs, 2000, 7, 225-232.	3.8	22
489	Non-Platinum Antitumor Compounds. , 1999, , 171-199.		10
490	Studies on the interactions between human serum albumin and imidazolium [trans-tetrachlorobis(imidazol)ruthenate(III)]. Journal of Inorganic Biochemistry, 1999, 73, 123-128.	1.5	74
491	Effect of cis-, trans-diamminedichloroplatinum(II) and DBP on human serum albumin. Journal of Inorganic Biochemistry, 1999, 77, 141-146.	1.5	59
492	Synthesis and structures of (SP-4-2)-diiodobis(2-hydroxyethylamine)platinum(II), (SP-4-2)-dichlorobis(2-hydroxyethylamine)platinum(II) and (OC-6-22)-bis(2-hydroxyethylamine)tetrachloroplatinum(IV) in the crystal. Inorganica Chimica Acta, 1999, 292, 127-130.	1.2	21
493	Investigation of metallodrugâ€“protein interactions by size-exclusion chromatography coupled with inductively coupled plasma mass spectrometry (ICP-MS). Analytica Chimica Acta, 1999, 387, 135-144.	2.6	99
494	Capillary electrophoretic study of cisplatin interaction with nucleoside monophosphates, di- and trinucleotides. Journal of Chromatography A, 1999, 852, 337-346.	1.8	35
495	Synthesis of Tumor-Inhibiting Complex Salts Containing the Aniontrans-Tetrachlorobis(indazole)ruthenate(III) and Crystal Structure of the Tetraphenylphosphonium Salt. European Journal of Inorganic Chemistry, 1999, 1999, 1551-1555.	1.0	54
496	Calcium Ions Do Accelerate the DNA Binding of New Antitumor-Active Platinum Aminophosphonate Complexes. European Journal of Inorganic Chemistry, 1999, 1999, 1655-1657.	1.0	39
497	Synthesis of Tumor-Inhibiting Complex Salts Containing the Anion trans-Tetrachlorobis(indazole)ruthenate(III) and Crystal Structure of the Tetraphenylphosphonium Salt. European Journal of Inorganic Chemistry, 1999, 1999, 1551-1555.	1.0	3
498	Imidazole release from the antitumor-active ruthenium complex imidazolium trans-tetrachlorobis(imidazole) ruthenate(III) by biologically occurring nucleophiles. Inorganica Chimica Acta, 1998, 267, 137-141.	1.2	36
499	Comparative nephrotoxicity of some antitumour-active platinum and ruthenium complexes in rats. Journal of Applied Toxicology, 1998, 18, 93-101.	1.4	37
500	Comparative nephrotoxicity of some antitumour-active platinum and ruthenium complexes in rats. , 1998, 18, 93.		1
501	Overview on bismuth(III) and bismuth(V) complexes with activity against Helicobacter pylori. Coordination Chemistry Reviews, 1997, 163, 345-364.	9.5	65
502	Synthesis of water-soluble ruthenium porphyrins as DNA cleavers and potential cytotoxic agents. Journal of Biological Inorganic Chemistry, 1997, 2, 427-432.	1.1	28
503	Carboxylation of dihydroxoplatinum(IV) complexes with acyl chlorides. Crystal structures of the trans-R,R- and trans-S,S-isomer of (OC-6-33)-bis(1-adamantanecarboxylato)-(cyclohexane-1,2-diamine)dichloroplatinum(IV). Inorganica Chimica Acta, 1997, 265, 271-274.	1.2	32
504	Two antitumour ruthenium(III) complexes showing selectivity in their binding towards poly(dG)Â·poly(dC) and poly(dA)Â·poly(dT). Chemical Communications, 1996, , 1741-1742.	2.2	14

#	Article	IF	Citations
505	Determination of platinum in protein-bound CDDP and DBP by inductively coupled plasma optical emission spectrometry and electrothermal atomic absorption spectrometry. Journal of Analytical Atomic Spectrometry, 1996, 11, 747-750.	1.6	27
506	Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of trans-1-Methyl-Indazoliumtetrachlorobis-(1-Methylindazole)Ruthenate(III) and its Hydrolysis Product trans-Monoaquatrichlorobis-(1-Methylindazole)-Ruthenate(III). Metal-Based Drugs, 1996, 3, 243-260.	3.8	104
507	Synthese und Struktur siebenfach koordinierter Bismut(ν)â€komplexe mit benzoiden und nichtbenzoiden Arenliganden: Tri(aryl)tropolonatobismut(<scp>V</scp>)â€komplexe. Angewandte Chemie, 1996, 108, 90-92.	1.6	2
508	Struktur von S-9,10-Dimethyl-1,3,5,7-tetraarsa-2,4,6,8-tetraoxaadamantan und 9,10-Diethyl-1,3,5,7-tetraarsa-2,4,6,8-tetraoxaadamantan. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 1996, 622, 1097-1100.	0.6	11
509	Overview of Tumor-Inhibiting Non-Platinum Compounds. , 1996, , 253-268.		1
510	Preparation and Characterization of Biologically Active Bismuth(III) Tropolonato Complexes. Chemische Berichte, 1995, 128, 335-342.	0.2	33
511	First Isolation of an Enol of a Carboxylic Acid by Complexation to an(Ethane-1,2-diamine)-platinum(II) Fragment. Angewandte Chemie International Edition in English, 1995, 34, 1103-1104.	4.4	15
512	Five-Coordinate Platinum Olefin Complexes: Synthesis, 1H NMR Investigations, and Crystal Structure of a Platinum .eta.2-Ethylene Crown Ether Complex. Inorganic Chemistry, 1995, 34, 2788-2790.	1.9	6
513	Structure of an Antineoplastic Platinum Complex with a Bipyridylâ€“Crown Ether. Angewandte Chemie International Edition in English, 1994, 33, 186-188.	4.4	34
514	Solution Structures and Isomer Distributions of Bis(.beta.-diketonato) Complexes of Titanium(IV) and Cobalt(III). Inorganic Chemistry, 1994, 33, 3396-3400.	1.9	52
515	Aquation of the anticancer complex trans-[RuCl4(Him)2]â€“(Him = imidazole). Journal of the Chemical Society Dalton Transactions, 1994, , 3305-3310.	1.1	54
516	Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats. Journal of Cancer Research and Clinical Oncology, 1992, 118, 195-200.	1.2	54
517	Clinical Studies with Budotitane â€" A New Non-Platinum Metal Complex for Cancer Therapy. Progress in Clinical Biochemistry and Medicine, 1989, , 217-223.	0.5	13